US Patent 7923563 Amorphous object of cinnamide compound
Patent 7923563 was granted and assigned to Eisai on April, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+461 characters)
Article
Patent abstract
An amorphous object of (3E)-1-[l(s)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4methyl-1H-imidazol-1-yl)benzylidene]piperidine-2-one, which is represented by the formula (1) and has Aβ-production inhibitory activity. The amorphous object has such satisfactory properties that it has excellent solubility, is stable, does not readily become a crystalline form, and has low hygroscopicity. It is hence suitable for use in pharmaceutical preparations.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Eriko Doi0
Ikuo Kushida0
Koichi Ito0
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07923563 Amorphous object of cinnamide compound US Patent 7923563 Amorphous object of cinnamide compound
Infobox
Patent Number
079235630
Patent Number
79235630
Edits on 29 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079235630
Date of Patent
April 12, 2011
0Patent Application Number
116635500
Date Filed
October 25, 2005
0Official Website
Patent Primary Examiner
Edits on 19 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07923563 Amorphous object of cinnamide compound
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07923563
Date of patent
April 12, 2011
Patent application number
11663550
Date Filed
October 25, 2005
Patent primary examiner
Find more entities like US Patent 7923563 Amorphous object of cinnamide compound
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
